Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.

Shirish GadgeelAlice T ShawFabrice BarlesiLucio Crino James Chih-Hsin YangAnne-Marie DingemansDong-Wan KimFilippo de MarinisMathias SchulzShiyao LiuRavindra GuptaVlatka SmoljanovicSai-Hong Ignatius Ou

Published in: Lung Cancer (Auckland, N.Z.) (2019)

These data suggest that alectinib achieves a rapid response in patients, both systemically and in the CNS.

Keyphrases

phase ii
clinical trial
end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
open label
prognostic factors
diffuse large b cell lymphoma
artificial intelligence
patient reported